ERIS Lifesciences Ltd Share Price
As on 13 June 2026 at 01:12 IST
Eris Lifesciences Q1 FY26 Results:
Net profit rose 42% to ₹118 crores, compared to ₹83 crores in Q1 FY25. Total income in Q1 FY26 increased 8% to ₹776 crores from ₹721 crores in the same period last year.
About ERIS Lifesciences Ltd
Eris Lifesciences Ltd is a prominent Indian pharmaceutical company. The company operates in the pharmaceutical sector, specifically in branded formulations. It was founded in 2007 and has been in business for many years. The headquarters of Eris Lifesciences is located in the city of Ahmedabad in Gujarat. The company offers a variety of products, including medications for hypertension, diabetes, metabolic disorders, and other therapeutic areas. Their product portfolio also includes capsules and sachets. Eris Lifesciences Ltd’s commitment to innovation and quality has established it as a trusted name in the healthcare sector. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-0.78%
Over 6 Months
-14.15%
Over 1 Year
-20.39%
Over 3 Years
106.94%
ERIS Lifesciences Ltd Summary
Close ₹1,365.60
Open ₹1,365
High ₹1,400
Low ₹1,337.60
Volume 62,932
Net Turnover (in Cr) ₹8.64
52Wk High ₹1,910
52Wk Low ₹1,200
52Wk High / Low
1,200
1,910
ERIS Lifesciences Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹18,922.75
EPS (TTM) 18.33
Book Value (BV) 230.61
Div. Yield 0.53 %
P/E (TTM) 77.61
Price/Book Value 5.93
Delivery % 51.74 %
Face Value 1
Key Ratios
PE Ratio 249.38
PB Ratio 7.67
EV to Sales 12.58
PEG Ratio -3.36
ROA 1.61
ROE 3.07
Debt-Equity 0.96
Net Profit Margin 4.54
Operating Profit Margin 30.64
ERIS Lifesciences Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 2,912 | 2,032.97 | 1,696.30 | 1,373.14 | 1,220.57 |
| Total Expenses | 2,423.19 | 1,601.63 | 1,291.66 | 930.94 | 826.07 |
| Profit Before Tax | 488.87 | 431.34 | 404.64 | 442.20 | 394.50 |
| Profit After Tax | 374.67 | 397.12 | 374.16 | 405.79 | 355.13 |
| Operating Profit After Depreciation | 720.10 | 516.14 | 430.81 | 446.34 | 396.30 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 5,306.75 | 4,319.77 | 2,568.45 | 920.92 | 855.43 |
| Total Non Current Assets | 5,810.18 | 4,738.42 | 2,902.61 | 1,644.81 | 1,367.73 |
| Total Current Assets | 1,222.99 | 2,302.04 | 764.72 | 627.33 | 467.05 |
| Total Assets | 7,033.17 | 7,040.46 | 3,667.33 | 2,272.14 | 1,834.78 |
| Total Shareholder's Fund | 2,854.36 | 2,586.18 | 2,195.99 | 1,908.31 | 1,576.42 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,065.01 | 486.01 | 291.74 | 378.26 | 375.36 |
| Net Cash Used In Investing Activities | -78.20 | -1,827.66 | -974.61 | -319.61 | -323.36 |
| Net Cash Used In Financing Activities | -881.32 | 1,379.78 | 688.03 | -44.70 | -82.40 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,733.26 | 1,521.54 | 1,347.99 | 1,244.72 | 1,118.83 |
| Total Expenses | 1,613.21 | 1,192.70 | 911.08 | 786.18 | 729.94 |
| Profit Before Tax | 120.05 | 328.84 | 436.91 | 458.54 | 388.89 |
| Profit After Tax | 77.39 | 299.72 | 398.01 | 417.19 | 350.61 |
| Operating Profit After Depreciation | 340.29 | 386.26 | 457.72 | 461.53 | 389.67 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 2,412.45 | 1,516.17 | 898.16 | 644.99 | 585.88 |
| Total Non Current Assets | 4,594.89 | 3,473.03 | 2,231.58 | 1,570.41 | 1,331.17 |
| Total Current Assets | 627.54 | 1,876.54 | 552.08 | 580.01 | 423.63 |
| Total Assets | 5,222.43 | 5,349.57 | 2,783.66 | 2,150.42 | 1,754.80 |
| Total Shareholder's Fund | 2,514.90 | 2,524.02 | 2,221.88 | 1,918.56 | 1,575.47 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 701.86 | 336.29 | 322.33 | 369.41 | 395.41 |
| Net Cash Used In Investing Activities | -358.99 | -2,491.89 | -513.30 | -267.64 | -347.86 |
| Net Cash Used In Financing Activities | -310.46 | 2,160.05 | 193.75 | -88.42 | -81.13 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 756.56 | 807.45 | 792.41 | 773 | 705.30 |
| Total Expenses | 484.19 | 525.84 | 504.20 | 496.29 | 452.91 |
| Profit Before Tax | 159.41 | 145.35 | 172.67 | 161.10 | 128.87 |
| Profit After Tax | 279.10 | 108.83 | 134.47 | 125.10 | 102.35 |
| Operating Profit after Depreciation | 274.60 | 281.75 | 291.30 | 280.29 | 260.40 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 277.31 | 315.29 | 650.50 | 578.64 | 404.77 |
| Total Expenses | 255.53 | 237.94 | 353.62 | 362.32 | 283.80 |
| Profit Before Tax | -32.77 | 3.89 | 234.67 | 156.26 | 41.18 |
| Profit After Tax | -8.60 | 3.09 | 149.57 | 99.99 | 30.47 |
| Operating Profit after Depreciation | 48.75 | 102.42 | 320.47 | 239 | 137.72 |
ERIS Lifesciences Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 1,335.47
S2 1,305.33
S3 1,273.07
Pivot 1,367.73
R1 1,397.87
R2 1,430.13
R3 1,460.27
Moving Average
20 SMA 1,370.79
50 SMA 1,367.05
100 SMA 1,370.57
200 SMA 1,494.18
ERIS Lifesciences Ltd Corporate Actions
ERIS Lifesciences Ltd
₹7.21/Share
Announcement Date 29 May 2026
Record Date 29 May 2026
Div Yield 721%
ERIS Lifesciences Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
ERIS Lifesciences Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Mirae Asset Healthcare Fund | 3.25% |
| HDFC Small Cap Fund | 2.37% |
| Franklin India Small Cap Fund | 2.26% |
| HDFC Hybrid Equity Fund | 1.57% |
| Franklin India Opportunities Fund | 1.15% |
ERIS Lifesciences Ltd News
Board of ERIS Lifesciences recommends interim dividend
Of Rs 7.21 per share
20 May 2026, 03:34 pm
Eris Lifesciences spurts after Q4 PAT skyrockets 200% YoY to Rs 282 cr
Eris Lifesciences surged 8.57% to Rs 1,455.25 after the company's consolidated net profit zoomed 200.09% to Rs 281.61 crore in Q4 FY26 as against Rs 93.84 crore in Q4 FY25.
20 May 2026, 03:19 pm
ERIS Lifesciences to hold board meeting
On 20 May 2026
16 May 2026, 06:09 pm
ERIS Lifesciences allots 24,396 equity shares under ESOP
11 May 2026, 11:50 am
Eris Lifesciences receives affirmation in credit ratings
09 May 2026, 12:05 pm
ERIS Lifesciences Ltd Stock Analysis
- Annual revenue for ERIS Lifesciences Ltd increased by 13.91% to ₹1,733.26 crore in FY 2025 from ₹1,521.54 crore in FY 2024.
- Annual Net Profit for ERIS Lifesciences Ltd decreased by 74.18% to ₹77.39 crore in FY 2025 from ₹299.72 crore in FY 2024.
- Promoter Shareholding in ERIS Lifesciences Ltd decreased by 1.68% in the most recent quarter, from 54.85% in December 2025 to 53.92% in March 2026.
- ERIS Lifesciences Ltd delivered a 1-year return of -20.39% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
- ERIS Lifesciences Ltd share price moved up by 0.44% from its previous close of INR ₹1,365.60. The latest ERIS Lifesciences Ltd share price is INR ₹1,371.60.
- ERIS Lifesciences Ltd share price today has been at a low of 1,365.30 and a high of 1,388. Over the past 52 weeks, the ERIS Lifesciences Ltd share price has seen a low of 1,200 and a high of 1,910.
About ERIS Lifesciences Ltd
Eris Lifesciences Ltd is a prominent Indian pharmaceutical company that develops pharmaceutical formulations. The company focuses mainly on chronic and sub-chronic diseases. It offers a diverse range of products in the cardio-metabolic and nephrology segments.
Eris Lifesciences operates in the pharmaceutical sector, specifically within the branded formulations market. Founded in 2007, Eris Lifesciences has been in business for many years. The company’s headquarters is located in Ahmedabad, Gujarat, India. The key promoters of Eris Lifesciences include Amit Bakshi, with a 42.87% stake in the company. He is also the Chairman and Managing Director. Apart from him, a team of professional managerial promoters manages the daily operations of the company. They are
Eris Lifesciences holds a significant position in the Indian pharmaceutical market, particularly in the cardio-metabolic segment. However, it is not the most significant player in terms of market share or market capitalization. The promoters hold a substantial share in the company, ensuring strong leadership in the company.
The registered office of Eris Lifesciences is in Ahmedabad, Gujarat and the office of the registrars is in Mumbai, Maharashtra. The company continues to make significant strides in the pharmaceutical industry. It also focuses on improving patient care and expanding its product offerings to address chronic and lifestyle-related diseases. Its commitment to innovation and quality has made it a trusted name in the healthcare sector.
Eris Lifesciences has a strong emphasis on research and development. The company invests in cutting-edge technologies to stay at the forefront of innovation. It also focuses on scientific research to develop new and improved formulations. Their R&D efforts aim to create better efficacy and patient compliance medications. This focus on innovation ensures they stay ahead in the competitive pharmaceutical market.
The company places a high value on collaboration. Eris Lifesciences works closely with healthcare professionals to ensure its products meet industry needs. The company also engages with other stakeholders to address the evolving demands of the healthcare sector. These collaborations help them gain insights into the latest medical advancements and incorporate them into product development.
Eris Lifesciences is committed to maintaining the highest quality standards in all its products. The company adheres to stringent quality control measures at every stage of the manufacturing process. This commitment to quality ensures that their products are safe and effective for patients. It also helps build trust and credibility with healthcare providers and patients.
The company’s vision extends beyond just providing medications. Eris Lifesciences aims to be a holistic healthcare provider. It offers various patient care initiatives and support programs that help patients manage their conditions better. These initiatives include educational programs and patient support groups. Such efforts demonstrate their dedication to improving overall patient well-being.
Eris Lifesciences also focuses on sustainability and social responsibility. The company is committed to conducting its business in an environmentally responsible manner. It implements eco-friendly practices in its manufacturing processes to minimise its environmental footprint. Additionally, Eris Lifesciences engages in various social initiatives to improve community health and well-being.
The company’s vision is also reflected in its growth strategy. Eris Lifesciences aims to expand its presence in both domestic and international markets. It seeks to achieve this through strategic acquisitions and by entering new therapeutic areas. This growth strategy is aligned with its vision of making a broader impact on global healthcare.
Eris Lifesciences believes in the continuous development of its workforce. The company invests in training and development programs for its employees. These programs are designed to enhance their skills and knowledge. A motivated and skilled workforce is a crucial driver of their success.
The company’s leadership plays a crucial role in driving its vision. The promoters and management team are committed to upholding the company’s values and guiding it towards achieving its goals. Their strategic direction and decision-making align with the company’s vision of improving patient care and positively impacting healthcare.
Eris Lifesciences also emphasises the importance of ethical business practices. The company operates with integrity and transparency in all its dealings. This ethical approach helps build strong relationships with stakeholders and fosters a culture of trust.
The company’s vision is business growth and making a meaningful difference in patients' lives. Eris Lifesciences is dedicated to creating a healthier future for all. Its efforts are focused on providing innovative healthcare solutions that improve patient outcomes and enhance the quality of life.
Eris Lifesciences operates in the pharmaceutical sector, specifically within the branded formulations market. Founded in 2007, Eris Lifesciences has been in business for many years. The company’s headquarters is located in Ahmedabad, Gujarat, India. The key promoters of Eris Lifesciences include Amit Bakshi, with a 42.87% stake in the company. He is also the Chairman and Managing Director. Apart from him, a team of professional managerial promoters manages the daily operations of the company. They are
- Krishnakumar Vaidyanathan
- Inderjeet Singh Negi
- Kaushal Shah
- Rajeev Dalal
Eris Lifesciences holds a significant position in the Indian pharmaceutical market, particularly in the cardio-metabolic segment. However, it is not the most significant player in terms of market share or market capitalization. The promoters hold a substantial share in the company, ensuring strong leadership in the company.
The registered office of Eris Lifesciences is in Ahmedabad, Gujarat and the office of the registrars is in Mumbai, Maharashtra. The company continues to make significant strides in the pharmaceutical industry. It also focuses on improving patient care and expanding its product offerings to address chronic and lifestyle-related diseases. Its commitment to innovation and quality has made it a trusted name in the healthcare sector.
Vision of Eris Lifesciences Limited
Eris Lifesciences Ltd envisions making a significant impact in managing chronic lifestyle-related diseases. It aims to improve patient outcomes through innovative and high-quality pharmaceutical products. The company’s vision fuels its dedication to addressing the healthcare needs of patients with chronic conditions. This includes a strong focus on diabetes and cardiovascular diseases.Eris Lifesciences has a strong emphasis on research and development. The company invests in cutting-edge technologies to stay at the forefront of innovation. It also focuses on scientific research to develop new and improved formulations. Their R&D efforts aim to create better efficacy and patient compliance medications. This focus on innovation ensures they stay ahead in the competitive pharmaceutical market.
The company places a high value on collaboration. Eris Lifesciences works closely with healthcare professionals to ensure its products meet industry needs. The company also engages with other stakeholders to address the evolving demands of the healthcare sector. These collaborations help them gain insights into the latest medical advancements and incorporate them into product development.
Eris Lifesciences is committed to maintaining the highest quality standards in all its products. The company adheres to stringent quality control measures at every stage of the manufacturing process. This commitment to quality ensures that their products are safe and effective for patients. It also helps build trust and credibility with healthcare providers and patients.
The company’s vision extends beyond just providing medications. Eris Lifesciences aims to be a holistic healthcare provider. It offers various patient care initiatives and support programs that help patients manage their conditions better. These initiatives include educational programs and patient support groups. Such efforts demonstrate their dedication to improving overall patient well-being.
Eris Lifesciences also focuses on sustainability and social responsibility. The company is committed to conducting its business in an environmentally responsible manner. It implements eco-friendly practices in its manufacturing processes to minimise its environmental footprint. Additionally, Eris Lifesciences engages in various social initiatives to improve community health and well-being.
The company’s vision is also reflected in its growth strategy. Eris Lifesciences aims to expand its presence in both domestic and international markets. It seeks to achieve this through strategic acquisitions and by entering new therapeutic areas. This growth strategy is aligned with its vision of making a broader impact on global healthcare.
Eris Lifesciences believes in the continuous development of its workforce. The company invests in training and development programs for its employees. These programs are designed to enhance their skills and knowledge. A motivated and skilled workforce is a crucial driver of their success.
The company’s leadership plays a crucial role in driving its vision. The promoters and management team are committed to upholding the company’s values and guiding it towards achieving its goals. Their strategic direction and decision-making align with the company’s vision of improving patient care and positively impacting healthcare.
Eris Lifesciences also emphasises the importance of ethical business practices. The company operates with integrity and transparency in all its dealings. This ethical approach helps build strong relationships with stakeholders and fosters a culture of trust.
The company’s vision is business growth and making a meaningful difference in patients' lives. Eris Lifesciences is dedicated to creating a healthier future for all. Its efforts are focused on providing innovative healthcare solutions that improve patient outcomes and enhance the quality of life.
FAQ’s
What is the share price of ERIS Lifesciences Ltd today?
ERIS Lifesciences Ltd share price as on 12 Jun 2026 is ₹ 1371.6
What is the Market Cap of ERIS Lifesciences Ltd?
The market cap of ERIS Lifesciences Ltd stock is ₹18,922.75 Cr.
What is the PE Ratio of ERIS Lifesciences Ltd?
The Price to Earnings (P/E) Ratio of ERIS Lifesciences Ltd is 249.38
What is the PB Ratio of ERIS Lifesciences Ltd?
The Price to Book (P/B) Ratio of ERIS Lifesciences Ltd is 7.67
What is the 52 week high of ERIS Lifesciences Ltd Share Price?
The 52 week high of ERIS Lifesciences Ltd share price stands at ₹1,910
What is the 52 week low of ERIS Lifesciences Ltd Share Price?
The 52 week low of ERIS Lifesciences Ltd share price stands at ₹1,200
How can I buy shares of ERIS Lifesciences Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of ERIS Lifesciences Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
